Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization

Recruiting now

Conditions studied: RSV Infection

In brief

A longitudinal observational study based on routinely collected data on hospital and health care use for RSV infections will be undertaken. The Galician public health registries will be used for data collection including baseline information and follow-up data. Historical data will be retrieved for comparison purposes. The study aims to observe and analyze data from all the eligible children in Galicia for nirsevimab treatment. The number of eligible children is expected to be approximately 14,000 per each RSV season.

Key facts

Study ID

NCT06180993

Run by

Federico Martinón Torres

People needed

42000

Starts

2023-09-25

Expected to finish

2026-10-31

Last updated by the study team

2023-12-26

Who can join

Age: 0 and older, up to 2. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects born in Galicia from April 1st, 2023 and March 1st, 2026

You may not qualify if…

• No specific criteria has been reported

Where it is running

• Hospital Clínico Universitario de Santiago de Compostela — Santiago de Compostela, A Coruña, Spain (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.